Skip to main navigation Skip to search Skip to main content

Fractional ablative CO 2 laser followed by topical application of sodium stibogluconate for treatment of active cutaneous leishmaniasis: A randomized controlled trial

  • Ofir Artzi*
  • , Eli Sprecher
  • , Amir Koren
  • , Joseph N. Mehrabi
  • , Oren Katz
  • , Yuval Hilerowicz
  • *Corresponding author for this work
  • Tel Aviv Sourasky Medical Center
  • Tel Aviv University

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Conventional treatment of cutaneous leishmaniasis often leaves permanent scars with frequent psychosocial sequelae. The aim of this study was to compare the efficacy, safety, associated pain and final cosmetic outcome of fractional carbon dioxide (CO 2 ) laser followed by topical application of sodium stibogluconate vs. sodium stibogluconate injections for the treatment of cutaneous leishmaniasis. A total of 181 lesions (20 patients) were randomly assigned to receive intrale-sional injections of sodium stibogluconate (control group) or fractional CO laser treatment followed by 2 topical application of sodium stibogluconate (study group). The visual analogue scale (VAS) score of the control group was much higher than that of the study group (6.85 vs. 3.5, respectively, p < 0.001). Both the patients and 2 blinded dermatologists found the final cosmetic outcome to be superior for laser-treated lesions (p = 0.001 vs. p =0.008 for controls). Fractional CO 2 laser treatment followed by topical application of sodium stibogluconate is less painful and leads to a better final cosmetic outcome compared with intrale-sional injections of sodium stibogluconate.

Original languageEnglish
Pages (from-to)53-57
Number of pages5
JournalActa Dermato-Venereologica
Volume99
Issue number1
DOIs
StatePublished - 1 Jan 2018

Keywords

  • Ablative fractional laser
  • Carbon dioxide
  • Cutaneous leishmaniasis
  • Drug delivery

Fingerprint

Dive into the research topics of 'Fractional ablative CO 2 laser followed by topical application of sodium stibogluconate for treatment of active cutaneous leishmaniasis: A randomized controlled trial'. Together they form a unique fingerprint.

Cite this